<DOC>
	<DOCNO>NCT00838565</DOCNO>
	<brief_summary>This study evaluate safety tolerability PF-04236921 administer monthly three intravenous infusion . Each group patient assign dose level ; Safety tolerability low dose level require proceed successively high dose level . Blood test perform measure amount drug change measure inflammation .</brief_summary>
	<brief_title>Phase I Study Of The Safety , Tolerability , Pharmacokinetics And Pharmacodynamics Of Multiple Intravenously Administered Doses Of PF-04236921 In Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description>Safety Tolerability Pharmacokinetic/Pharmacodynamic assessment inflammation-related biomarkers .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Rheumatoid Arthritis stable dose methotrexate Rheumatoid Arthritis disease activity assess blood test Serious uncontrolled medical condition Current recent treatment diseasemodifying drug methotrexate include limited leflunomide , sulfasalazine , etanercept , infliximab , adalimumab , abatacept , rituximab Current oral glucocorticoid dose 10 mg/d prednisone equivalent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Safety tolerability Pharmacokinetics Pharmacodynamics PF-04236921</keyword>
</DOC>